IDMI @$1.97. See previous post re: European approval of "Mepact" (L-MTP-PE or Junovan) either in February or March 2009. Rodman and Renshaw analyst projects $20M revenue tops in Europe alone. About 29M shares outstanding, x5 revs of $20M= $100M. $100M div by 29M shares= about $3.50 a share.
IDM is either going to be bought out or partner, probably buy-out, since CEO and other executive officers are working part-time at IDM.
I have admit that "Mr. Market" is stumping me re: current share price of about $2.00 on this one. Of course overall market is in a massive deleveraging.
I own IDMI, do your own DD. GLTA